Tsampras Nikolaos, Gould Della, Fitzgerald Cheryl T
a St Mary's Hospital Reproductive Medicine Unit , Manchester , UK.
Hum Fertil (Camb). 2017 Dec;20(4):248-253. doi: 10.1080/14647273.2017.1287433. Epub 2017 Feb 9.
This article describes a revised ovarian stimulation protocol (DuoStim) for fertility preservation in female oncology patients which aims to maximise the number of gametes obtained with subsequent improvement in cumulative birth rate, without delaying cancer treatment. Ten patients diagnosed with malignancy between September 2014 and October 2015 were included. The patients were treated with the DuoStim protocol, undergoing two consecutive ovarian stimulation cycles and two oocyte retrievals. The primary outcome was the number of oocytes collected and vitrified during each oocyte retrieval and in total. The protocol was evaluated regarding medical risk and patients' feedback. During the first oocyte collection 81 oocytes (61 metaphase II) were retrieved (mean = 8.1; range = 1-13) and during the second oocyte collection 82 oocytes (67 metaphase II) were retrieved (mean= 8.2; range = 1-19). A total of 163 oocytes (128 metaphase II) were collected (mean = 16.3; range = 6-32) and cancer treatment was not delayed for any of these patients. There were no cases of ovarian hyperstimulation syndrome recorded. More patients and long-term follow-up is needed to assess the efficacy and safety of the DuoStim protocol. However, these early results are encouraging, demonstrating an increase in number of mature oocytes retrieved during ovarian stimulation for oncology patients, without delaying cancer treatment.
本文描述了一种用于肿瘤女性患者生育力保存的改良卵巢刺激方案(DuoStim),其目的是在不延迟癌症治疗的情况下,使获得的配子数量最大化,从而提高累积出生率。纳入了2014年9月至2015年10月期间诊断为恶性肿瘤的10例患者。这些患者接受了DuoStim方案治疗,连续进行了两个卵巢刺激周期和两次卵母细胞采集。主要结局是每次卵母细胞采集及总共采集并玻璃化的卵母细胞数量。对该方案的医疗风险和患者反馈进行了评估。在第一次卵母细胞采集时,获取了81枚卵母细胞(61枚处于中期II)(均值 = 8.1;范围 = 1 - 13),在第二次卵母细胞采集时,获取了82枚卵母细胞(67枚处于中期II)(均值 = 8.2;范围 = 1 - 19)。总共采集了163枚卵母细胞(128枚处于中期II)(均值 = 16.3;范围 = 6 - 32),且这些患者均未延迟癌症治疗。未记录到卵巢过度刺激综合征病例。需要更多患者和长期随访来评估DuoStim方案的疗效和安全性。然而,这些早期结果令人鼓舞,表明在不延迟癌症治疗的情况下,肿瘤患者卵巢刺激期间获取的成熟卵母细胞数量有所增加。